Neonatal Sepsis Treatment Guidelines

First-Line Empiric Therapy

• The World Health Organization recommends ampicillin plus gentamicin as the first-line empiric treatment for early-onset neonatal sepsis, providing coverage against Group B Streptococcus, E. coli, and Listeria monocytogenes 1, 2, 3
• This combination is effective against the most common early-onset pathogens, with approximately 92% of Gram-negative isolates remaining susceptible to the ampicillin-gentamicin combination 4, 5

Late-Onset and Nosocomial Sepsis

• The World Health Organization recommends amikacin plus cloxacillin as the first-line empiric therapy for hospital-acquired neonatal infections, providing coverage against resistant staphylococci and Gram-negative bacteria 4, 2
• Vancomycin plus ceftazidime should replace the above when methicillin-resistant staphylococci or resistant Gram-negative bacteria are suspected 4

Escalation and Modification of Therapy

• The American Academy of Pediatrics recommends adding cefotaxime when there is evidence or strong suspicion of Gram-negative sepsis 1, 2, 3
• Therapy should be escalated immediately if no clinical improvement occurs after 48-72 hours of initial empiric therapy, or if blood cultures reveal organisms resistant to the initial regimen 4, 3

Regional Considerations and Resistance Patterns

• The initial empiric choice must be modified by knowledge of local bacterial epidemiology and resistance patterns, with less than one-quarter of neonates globally receiving WHO-recommended first- or second-line antibiotics 4, 5
• In low- and middle-income countries, 97% of Gram-negative isolates show ampicillin resistance, and resistance to ceftriaxone is similarly concerning 5

Critical Timing Considerations

• Antibiotics should be initiated within 1 hour for septic shock, and within 3 hours for sepsis without shock 4, 3
• Blood cultures should be obtained before antibiotic administration, but never delay treatment waiting for results 4, 2